OncoMatch/Clinical Trials/NCT05824585
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Is NCT05824585 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies DZD8586 for lymphoma, non-hodgkin.
Treatment: DZD8586 — This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior history of allogeneic hematopoietic stem cell transplantation
Cannot have received: stem cell transplantation
Exception: within 90 days
Stem cell transplantation, cell therapy, or gene therapy within 90 days
Cannot have received: cell therapy
Exception: within 90 days
Stem cell transplantation, cell therapy, or gene therapy within 90 days
Cannot have received: gene therapy
Exception: within 90 days
Stem cell transplantation, cell therapy, or gene therapy within 90 days
Cannot have received: approved small molecule therapy
Exception: within 5 half-lives
Approved small molecule therapy within 5 half-lives
Cannot have received: investigational small molecule therapy
Exception: within 14 days
investigational small molecule therapy within 14 days
Cannot have received: monoclonal antibody
Exception: within 28 days
Monoclonal antibodies and antibody-drug conjugates within 28 days
Cannot have received: antibody-drug conjugate
Exception: within 28 days
Monoclonal antibodies and antibody-drug conjugates within 28 days
Cannot have received: radiation therapy
Exception: within 1 weeks
Radiation therapy within 1 weeks
Lab requirements
Blood counts
adequate bone marrow reserve
Kidney function
adequate organ system functions
Liver function
adequate organ system functions
Adequate bone marrow reserve and organ system functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research site · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05824585 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplantation, stem cell transplantation, cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages